Workshop highlights include:
- Breaking down case studies of progressing ADC development across Phase I-III clinical trails
- Delving into exposure response modeling and analysis to inform ADC dosing and clinical activity
- Finding the right patient for the right ADC: evaluating when and how to implement patient cut-off criteria